TC Biopharm and the NIPRO Corporation Announce Strategic Programme Co-Developing a Novel Gamma-Delta Car-T Product to Treat Cancer

From Drug Discovery Today - February 8, 2018

The NIPRO Corporation (TSE: 8086) and TC BioPharm Ltd (TCB) announced today that they have formed a strategic collaboration to co-develop a novel immunotherapy product using TCBs safe CAR-T platform, based on unique properties of modified gamma delta () T cells to selectively target cancer whilst leaving healthy cells untouched. TCB intends to use this novel platform to develop new CAR-based immunotherapies, with the aim of treating a broad range of cancers and major viral disease.

TCBs chief operating officer, Angela Scott, said: TCBs world-class GMP-compliant manufacturing facility and experienced in-house clinical team will allow us to leverage patient treatment at established cancer therapy centers throughout Europe. Since commencing operations in 2014, we have treated numerous cancer patients successfully with unmodified gamma-delta T cells and built sufficient infrastructure to progress our innovative proprietary next-generation CAR-T towards phase I studies during 2018.

The NIPRO Corporation will provide non-dilutive funds in the form of up-front fees, milestone payments and research support to progress elements of TCBs CAR-T program to clinical studies. NIPRO cash will provide the Osaka-based company with an exclusive right to sell and distribute CAR-T product worldwide.

TCB and NIPRO will co-develop an autologous gamma-delta CAR-T therapy directed against CD19, which is expressed in several blood cancers such as multiple myeloma and lymphoma. Preclinical studies developing the product will be supported by a Scottish Enterprise seek-and-solve grant which will provide 2.7m of additional non-dilutive funding.

Continue reading at Drug Discovery Today »